BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $15.5 million in its fourth quarter.
On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 24 cents.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.
The biotechnology company posted revenue of $14.1 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $13.6 million.
For the year, the company reported a loss of $71 million, or 97 cents per share. Revenue was reported as $51.5 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OCUL at https://www.zacks.com/ap/OCUL
Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
